Year Founded
2020
Ownership
Private
Employees
~50
Stage
Preclinical
Modalities
Antibody-based immunotherapyImmune checkpoint inhibitors

Pheast Therapeutics General Information

Developing anti-CD24 antibodies showing tumor clearance in preclinical models of triple-negative breast cancer through enhanced macrophage-mediated phagocytosis

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Palo Alto, California
United States

Drug Pipeline

PHST001
Pre-clinical
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Pheast Therapeutics's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Pheast Therapeutics Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Pheast Therapeutics's complete valuation and funding history, request access »

Pheast Therapeutics Investors

ARCH Venture Partners
Investor Type: Venture Capital
Holding: Minority
Catalio Capital Management
Investor Type: Venture Capital
Holding: Minority
Alexandria Venture Investments
Investor Type: Venture Capital
Holding: Minority
Investor Name
Investor Type
Holding
Investor Name
Investor Type
Holding
You're viewing 3 of 4 investors. Get the full list »